José Luis Manzano Mozo

Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study

Philip A. Philip, Jill Lacy, Fabienne Portales et al. · ˜The œLancet. Gastroenterology & hepatology · 2020 · 246 citations

Medicine, Oncology, Pharmacology +10

Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer

Thierry André, Elena Élez, Eric Van Cutsem et al. · New England Journal of Medicine · 2024 · 213 citations

Medicine, Oncology, Pharmacotherapy +17

Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial

Thierry André, Elena Élez, Heinz‐Josef Lenz et al. · The Lancet · 2025 · 179 citations

Medicine, Oncology, Immunotherapy +12

Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: A phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801)

Daniel Castellano, Jaume Capdevila, Javier Sastre et al. · European Journal of Cancer · 2013 · 97 citations

Medicine, Oncology, Pharmacotherapy +13

Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study.

Thierry André, Elena Élez, Eric Van Cutsem et al. · Journal of Clinical Oncology · 2024 · 62 citations

Medicine, Oncology, Pharmacology +15